DEC-09-13 The National Viral Hepatitis Roundtable is seeking a candidate with a strong combination of viral hepatitis
knowledge and leadership experience to fill the position of Executive Director.Click here to see the job announcement. The application process is open until January 3,
2014. Resume, cover letter and any questions about the position may be
sent to Martha Saly at firstname.lastname@example.org
DEC-02-13 amfAR, The Foundation
for AIDS Research, and Treatment Action Group (TAG) called for a deliberate and
expedited research agenda designed to begin to end the AIDS epidemic in the
United States. The new report, Filling
the Gaps in the U.S. Treatment Cascade: Developing a Community-Driven Research
Agenda, summarizes key implementation science research priorities
developed at a June 2013 gathering of HIV community activists, researchers and
policy makers, and health care providers. Participants identified critical
areas for research and policy to address gaps in the United States continuum of
HIV care, also known as the HIV treatment cascade.
NOV-25-13 The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has given an opinion on the use of daclatasvir in combination with sofosbuvir in the treatment of chronic (long-term) hepatitis C virus (HCV) infection, in a compassionate-use programme. Click here to read the full press release.
NOV-25-13 The European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Sovaldi (sofosbuvir) intended for the treatment of chronic hepatitis C. Click here to read the full press release.
NOV-25-13 The U.S. Food and Drug Administration approved Olysio (simeprevir), a new therapy to treat chronic hepatitis C virus infection. Olysio is a protease inhibitor that blocks a specific protein needed by the hepatitis C virus to replicate. It is to be used as a component of a combination antiviral treatment regimen. Click here to read the full press release.
The 2012 National Summit on HIV and Viral Hepatitis Diagnosis,
Prevention, and Access
Care (November 26-28, 2012, Washington, DC) is sponsored by
for Collaborative HIV Research in partnership with the American Academy of HIV Medicine, amfAR, the American Academy of Nursing, the Hepatitis B Project, the Hepatitis Education
Project, the HIV Medicine Association, Kaiser Permanente, the National
Association of Community Health Centers, the NIH-NIAID Division of Acquired Immunodeficiency Syndrome, the National Black Gay Men's Advocacy Coalition, the National Viral
Hepatitis Roundtable, and the Office of HIV/AIDS and Infectious Disease Policy (HHS).
The mission of the 2012 Summit is to support improvement in HIV
and viral hepatitis testing, prevention, and linkage to care in the
United States. The nation’s public health scientific and advocacy
leadership will meet to discuss state-of-the-art mechanisms to support
the “National HIV/AIDS Strategy” and the HHS “Action Plan for the
Prevention, Care and Treatment of Viral Hepatitis.”
The program is being developed under the leadership of the
Dr. John G. Bartlett (Johns Hopkins University), Dr. Kenneth H.
(The Fenway Institute), and Dr. Veronica Miller (the Forum for Collaborative HIV Research), the Organizing Committee and the Scientific Advisory Committee
governmental agencies, professional societies, academia, clinical
community and advocacy organizations, and industry.
program will consist of plenary sessions and breakout sessions
in the areas of Routine and Expanded Testing, Prevention Models, Outcomes
and Impact Evaluation, and Access, Linkage and Retention in Care.
Goals and Objectives of the 2012 Summit are:
To address and support the
continued implementation of recommendations for increased HIV and viral
To further identify strategies
for reducing new HIV and viral hepatitis infections, increase access to
care and treatment, reduce related health disparities and reduce the
public health burden of HIV and viral hepatitis.
To strengthen viral hepatitis
surveillance, increase awareness and coverage of vaccine-preventable viral
To assess the current impact of differing
recommendations to implement routine HIV and viral hepatitis testing on
policy, program and practice at the local, state and federal level.
The 2012 Summit was held November 26-28, 2012 in Washington, DC.